Why Boston Scientific Stock Is Down Before Market Open

Boston Scientific Corporation fell 13% to $39.40 before regular trading began after a cybersecurity incident disrupted operations and hurt sales. The company lowered its full-year outlook as a result, signaling weaker expected results while it works to restore normal operations.

What Boston Scientific Corporation Does

Boston Scientific makes medical devices and therapies that help doctors diagnose and treat heart, lung, digestive, cancer, nerve, and urinary conditions. Its products serve several areas of medicine, rather than relying on one treatment. That broad reach matters because an operating disruption can affect sales across its business.

Boston Scientific Cybersecurity And Outlook

The company lowered its full-year sales-growth and adjusted-earnings forecasts after the incident affected sales. Adjusted earnings exclude certain items, and earnings per share shows profit for each share. For the next quarter, the company expects revenue to fall and adjusted earnings per share to come in below analysts’ average forecast.

Quick Financial Overview

Boston Scientific is a profitable large-cap, meaning the total value of its shares is high; its market value is $57.10B. Its latest balance sheet showed $539.0M in cash and cash equivalents, meaning cash the company can spend, as of June 30, 2026.

Boston Scientific Revenue And Earnings

Third-quarter net sales were $5.138 billion, up 1.5 percent from a year earlier and slightly above analysts’ average forecast. Adjusted earnings per share were $0.73, compared with $0.75 a year earlier and slightly above estimates. Profit remaining after expenses under standard accounting rules fell to $582 million from $755 million.

Boston Scientific Near Its 52-week Low

A month ago, Boston Scientific shares traded near the $45 level. They are now close to the bottom of their 52-week range, after falling down 23% over six months and down 55% over the past year. That longer decline shows the stock was already weak before this latest outlook change.

Conclusion

Boston Scientific’s next scheduled public event is a question-and-answer session at a healthcare investor conference on Wednesday, November 11, 2026. More detail on restoring operations could help investors judge whether the weaker outlook is temporary. If management offers little new clarity, the outlook will remain the clearest guide to near-term results.